Lupin Ltd (LUPIN) — Announcement | 4 September 2026
Lupin announced that the U.S. FDA approved its ANDA for Modafinil Tablets USP 100 mg and 200 mg, marking the company's first product launch in the U.S. generic wakefulness‑promotion market and expanding its presence in a $70.7 million therapeutic segment.
About Lupin Ltd (LUPIN)
Healthcare · Pharmaceuticals · Listed on BSE
📡 Get AI alerts when LUPIN files next
Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions
Track LUPIN — Free💡 Ask AI about this filing
📊 More LUPIN filings
- 🔴 Announcement — 28 September 2026Lupin announced that its U.S. subsidiary received tentative FDA approval for a novel apixaban oral s...
- Announcement — 28 September 2026Lupin Ltd announced that its insider trading window will close on October 1, 2026, and remain shut u...
- 🔴 Corporate Action — 21 September 2026Lupin announced on September 21, 2026, the allotment of 24,111 fully paid-up equity shares of ₹2 eac...
- 🔴 Announcement — 8 September 2026Lupin Ltd announced its participation in two upcoming investor events: the Kotak Healthcare Conferen...
- 🔴 Announcement — 28 August 2026Lupin Limited announced it received an ESG rating of Crisil ESG 69 and a Core ESG rating of Crisil C...
🔥 Also filed on 4 September 2026
Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.
Editorial & Data Transparency Notice
This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.
📡 Get AI alerts when LUPIN files new disclosures
Track LUPIN filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track LUPIN — FreeFree account · 2 AI queries/day